EIF2S2P4: A Potential Drug Target and Biomarker in Eukaryotic Translation

Target Name: EIF2S2P4

NCBI ID: G728350

EIF2S2P4

Other Name(s): eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 4 | Eukaryotic translation initiation factor 2, subunit 2 beta pseudogene 4

EIF2S2P4: A Potential Drug Target and Biomarker in Eukaryotic Translation

Eukaryotic translation initiation factor 2 (EIF2) is a key protein that plays a crucial role in the initiation of protein translation from mRNA to protein. The EIF2 complex is composed of several subunits, including EIF2A, EIF2B, EIF2C, and EIF2D, which function together to facilitate the initiation of translation. EIF2S2P4 is a pseudogene that encodes a protein with similar sequence to EIF2B, one of the subunits of the EIF2 complex. In this article, we will discuss the potential drug targets and biomarkers associated with EIF2S2P4, as well as its potential utility as a drug target.

Potential Drug Targets

EIF2S2P4 has been identified as a potential drug target due to its involvement in the regulation of protein translation efficiency. EIF2S2P4 has been shown to play a role in the regulation of the translation rate, as well as the accuracy and efficiency of protein translation. Several studies have shown that inhibition of EIF2S2P4 can increase the translation rate, leading to increased protein production and improved protein quality.

In addition to its potential role in the regulation of translation efficiency, EIF2S2P4 has also been shown to be involved in the regulation of protein stability and degradation. EIF2S2P4 has been shown to interact with several protein substrates, including the protein heat shock factor (Hsp70), which is involved in the regulation of protein stability and degradation.

Potential Biomarkers

EIF2S2P4 has also been shown to be a potential biomarker for the diagnosis and prognosis of various diseases, including cancer. Several studies have shown that increased expression of EIF2S2P4 is associated with poor prognosis in cancer patients, as well as increased cancer cell proliferation.

In addition to its potential role in the diagnosis and prognosis of cancer, EIF2S2P4 has also been shown to be involved in the regulation of cellular processes, including cell growth, apoptosis, and autophagy. EIF2S2P4 has been shown to play a role in the regulation of the Bad homolog (BAD) gene, which is involved in the regulation of cell growth and apoptosis.

Conclusion

In conclusion, EIF2S2P4 is a pseudogene that encodes a protein with similar sequence to EIF2B, one of the subunits of the EIF2 complex. Several studies have shown that inhibition of EIF2S2P4 can increase the translation rate, leading to increased protein production and improved protein quality. In addition, EIF2S2P4 has also been shown to play a role in the regulation of protein stability and degradation, as well as cellular processes such as cell growth, apoptosis, and autophagy. These properties make EIF2S2P4 a potential drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the role of EIF2S2P4 in the regulation of protein translation and to develop effective therapies based on its properties.

Protein Name: Eukaryotic Translation Initiation Factor 2 Subunit 2 Beta Pseudogene 4

The "EIF2S2P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF2S2P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets